A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Darunavir (PREZISTA)

Darunavir, co-administered with ritonavir (darunavir/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in....

First FDA approval2008-03-08
Generic availableYes · 10 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$81.7M in CY2024 Part D spend92K claims · 16K beneficiaries · 329 plans surveyed

Lowest NADAC
$1.13/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.64
Across all dosage forms in distribution.
Highest NADAC
$2.27
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Darunavir used for?

Darunavir, co-administered with ritonavir (darunavir/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in....

Is there a generic for Darunavir?

Yes. 23 ANDAs filed at FDA, 10 generic manufacturers currently shipping.

How much does my plan pay for Darunavir?

Across 329 Part D plans, Darunavir averages $1.64/unit (NADAC). Lowest available: $1.13/unit. Highest in distribution: $2.27/unit.

Is Darunavir on the FDA shortage list?

No. Darunavir is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Protease Inhibitor2 alternatives in D1
01
Atazanavir
Brand: Atazanavir Sulfate
$1.09Lowest NADAC
4Generic mfrs
$6.8MCY24 Part D spend
Compare →
02
Tipranavir
Brand: Aptivus
Lowest NADAC
0Generic mfrs
$1.5MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.